HQL (abrdn Life Sciences Investors) Insider Ownership: 0.71 % (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HQL abrdn Life Sciences Investors HQL
51 GF Score
Price $22.11
GF Value $62.01
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is abrdn Life Sciences Investors Insider Ownership?

abrdn Life Sciences Investors HQL -2.47% 51 Insider Ownership is 0.71 % as of Aug. 20, 2026. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, abrdn Life Sciences Investors's insider ownership is 0.71%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, abrdn Life Sciences Investors's Institutional Ownership is 27.20%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, abrdn Life Sciences Investors's Float Percentage Of Total Shares Outstanding is 0.00%.

abrdn Life Sciences Investors Insider Ownership Historical Data

* Premium members only.

The historical data trend for abrdn Life Sciences Investors's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Life Sciences Investors Insider Ownership Chart

abrdn Life Sciences Investors Historical Data

The historical data trend for abrdn Life Sciences Investors can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 0.74 0.74 0.74 0.74 0.74 0.72 0.72 0.70 0.70 0.71
HQL
51GF Score
abrdn Life Sciences Investors HQL
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

abrdn Life Sciences Investors Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.71 % mean?
abrdn Life Sciences Investors (HQL) has a Insider Ownership of 0.71 % as of Aug. 20, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on abrdn Life Sciences Investors and its competitors.
Is abrdn Life Sciences Investors' Insider Ownership too high?
abrdn Life Sciences Investors' current Insider Ownership is 0.71 %. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Insider Ownership compare to IIM and NOAH?
abrdn Life Sciences Investors' Insider Ownership of 0.71 % can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for an Asset Management company?
A good Insider Ownership depends on the Asset Management industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on abrdn Life Sciences Investors and its competitors. abrdn Life Sciences Investors's current Insider Ownership is 0.71 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.11 — trading 64.3% below its estimated fair value. The current Insider Ownership is 0.71 %. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Insider Ownership is 0.71 % as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued. The current stock price of $22.11 is trading 64.3% below its estimated GF Value™ of $62.01. GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.

Key valuation signals for HQL:

  • Insider Ownership: 0.71 %
  • GF Value™: $62.01 vs. price of $22.11 (64.3% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

abrdn Life Sciences Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score

Get the complete analysis for HQL

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.11
Price
$62.01
GF Value